D. Cooper

发表

Oral abstracts of the 21st International AIDS Conference 18–22 July 2016, Durban, South Africa

Michael I. Jordan, Donald A. Jackson, J. G. Ndirangu, 2016, Journal of the International AIDS Society.

No significant effect of uridine or pravastatin treatment for HIV lipoatrophy in men who have ceased thymidine analogue nucleoside reverse transcriptase inhibitor therapy: a randomized trial *

H. Wand, A. Calmy, C. Delhumeau, 2010, HIV medicine.

Evolution of CD4+ T cell count in HIV-1-infected adults receiving antiretroviral therapy with sustained long-term virological suppression.

A. Kelleher, S. Emery, K. Petoumenos, 2009, AIDS research and human retroviruses.

HIV and hepatitis C coinfection within the CAESAR study

D. Pillay, D. Cooper, G. Dore, 2004, HIV medicine.

Effect of nucleoside reverse transcriptase inhibitors on CD4 T‐cell recovery in HIV‐1‐infected individuals receiving long‐term fully suppressive combination antiretroviral therapy

D. Cooper, S. Emery, K. Petoumenos, 2009, HIV medicine.

Experience with the use of a first‐line regimen of stavudine, lamivudine and nevirapine in patients in the TREAT Asia HIV Observational Database

A. Vibhagool, D. Cooper, P. Phanuphak, 2007, HIV medicine.

HIV lipodystrophy: prevalence, severity and correlates of risk in Australia

S. Mallal, J. Kaldor, D. Cooper, 2003, HIV medicine.

Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment

K. Ruxrungtham, P. Phanuphak, P. Phanuphak, 2007, HIV medicine.

Indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96‐week outcomes of HIV‐NAT 009

K. Ruxrungtham, D. Cooper, P. Phanuphak, 2005, HIV medicine.

HIV‐associated lipodystrophy

D. Cooper, P. Mallon, A. Carr, 2001, HIV medicine.

Effects of IL‐2 therapy in asymptomatic HIV‐infected individuals on proliferative responses to mitogens, recall antigens and HIV‐related antigens

A. Kelleher, S. Emery, M. French, 1998, Clinical and experimental immunology.

Predictors of bacterial pneumonia in Evaluation of Subcutaneous Interleukin‐2 in a Randomized International Trial (ESPRIT)

D. Cooper, E. Lin, S. Emery, 2011, HIV medicine.

Influence of IFNγ Co-Expression on the Safety and Antiviral Efficacy of Recombinant Fowlpox Virus HIV Therapeutic Vaccines Following Interruption of Antiretroviral Therapy

A. Kelleher, S. Emery, R. Puls, 2007, Human vaccines.

Poly‐l‐lactic acid for HIV‐1 facial lipoatrophy: 48‐week follow‐up

S. Emery, K. Petoumenos, A. Carr, 2009, HIV medicine.

The public health impact of widespread availability of nonoccupational postexposure prophylaxis against HIV

A. Grulich, J. Kaldor, I. Poynten, 2007, HIV medicine.

Dynamics of cognitive change in HIV‐infected individuals commencing three different initial antiretroviral regimens: a randomized, controlled study

A. Winston, S. Taylor-Robinson, C. Duncombe, 2012, HIV medicine.

The use of a triple nucleoside‐nucleotide regimen for nonoccupational HIV post‐exposure prophylaxis

A. Winston, J. Amin, A. Carr, 2005, HIV medicine.

The effects of enfuvirtide therapy on body composition and metabolic parameters over 48 weeks in the TORO body imaging substudy *

P. Reiss, K. Arastéh, L. Rowell, 2011, HIV medicine.

Hyperlactataemia in HIV‐infected subjects initiating antiretroviral therapy in a large randomized study (a substudy of the INITIO trial)

D. Cooper, P. Yeni, R. Goodall, 2011, HIV medicine.

Therapeutic vaccination (p24‐VLP) of patients with advanced HIV‐1 infection in the pre‐HAART era does not alter CD4 cell decline

D. Cooper, S. Adams, R. Colebunders, 2001, HIV medicine.

Heterozygosity for CCR5‐DΔ32 but not CCR2b‐64I protects against certain intracellular pathogens

M. Law, J. Kaldor, D. Cooper, 2002, HIV medicine.

Characterization of the phenotypic and lymphokine profile associated with strong CD8+ anti‐HIV‐1 suppressor activity (CASA)

J. Zaunders, G. Guillemin, A. Carr, 2002, Clinical and experimental immunology.

Early changes in adipokine levels and baseline limb fat may predict HIV lipoatrophy over 2 years following initiation of antiretroviral therapy *

D. Cooper, H. Wand, M. Law, 2008, HIV medicine.

Effect of early initiation of highly active antiretroviral therapy on CD4 cell count and HIV‐RNA viral load trends within 24 months of the onset of acute retroviral syndrome *

N. Voirin, P. Vanhems, J. Routy, 2008, HIV medicine.

A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group.

L. M. Lehman, J. Leonard, A. Hsu, 1995, The New England journal of medicine.

Antiviral activity of apricitabine in treatment‐experienced HIV‐1‐infected patients with M184V who are failing combination therapy

P. Cahn, M. Losso, J. Altclas, 2011, HIV medicine.